Glycosyltransferases are essential tools for in vitro glycoengineering. Bacteria harbor an unexplored variety of protein glycosyltransferases. Here, we describe a peptide glycosyltransferase (EntS) encoded by ORF0417 of Enterococcus faecalis TX0104. EntS di-glycosylates linear peptide of enterocin 96 -a known antibacterial, in vitro. It is capable of transferring as well as extending the glycan onto the peptide in an iterative sequential dissociative manner. It can catalyze multiple linkages: Glc/Gal(-O)Ser/Thr, Glc/Gal(-S)Cys and Glc/Gal(β)Glc/Gal(-O/S)Ser/Thr/Cys, in one pot. Using EntS generated glycovariants of enterocin 96 peptide, size and identity of the glycan are found to influence bioactivity of the peptide. The study identifies EntS as an enzyme worth pursuing, for in vitro peptide glycoengineering.
Introduction
Glycosylation of proteins and peptides is common in bacteria. Several N-and O-glycosylated proteins are known in bacteria (Dell et al. 2010; Nothaft and Szymanski 2010; Bhat et al. 2012; Lu et al. 2015) . However, only three ribosomally produced, naturally glycosylated bacteriocins (glyco-bacteriocins) are characterized. Glycobacteriocins namely glycocin F, sublancin 168 and enterocin F4-9 are produced by Lactobacillus plantarum KW30 (Stepper et al. 2011) , Bacillus subtilis 168 (Oman et al. 2011) and Enterococcus faecalis F4-9 (Maky et al. 2015) , respectively. On the other hand, the bis-glycosylation of thurandacin (Bacillus thuringiensis BGSC 4AW1) at Ser19 and Cys28 is demonstrated in vitro (Wang et al. 2013 ). The glycan is important for bacteriostatic activity in glycocin F, enterocin F4-9 and refolded thurandacin. S-linked glycan in sublancin 168 imparts immunity to the producer organism against sublancin 168 via a self-resistance mechanism mediated through SunI -the immunity protein . Hitherto, only two glycosyltransferases (GTs) that are instrumental in S-/O-glycosylation of glyco-bacteriocins are validated, experimentally. While SunS is an S-glycosyltransferase that catalyzes the transfer of a monosaccharide in sublancin 168, ThuS is an O-and S-glycosyltransferase that transfers monosaccharide in thurandacin. Both these enzymes belong to the little explored GT-2 family of polyspecific GTs, wherein despite sequence similarities a huge variation exist in acceptor specificities of GTs (Lombard et al. 2014) . In this context, Table I provides a comparative understanding of GTs known or anticipated to glycosylate glyco-bacteriocins mentioned above.
Several bacterial GTs having relaxed substrate specificities are characterized in the past, where the aglycone is a small molecule in nature (Gantt et al. 2008 (Gantt et al. , 2013 . However, the direct applications of these GTs on peptide or protein as an acceptor is not known. Accordingly, protein/peptide GTs are a separate class of GTs. The emerging interests in antimicrobial peptides and their glycovariants as topical therapeutics, probiotic therapy, cosmetics or to generate conjugate vaccine (Hassan et al. 2012; Cotter et al. 2013) , provided motivation to study homologs of SunS and ThuS to identify novel specificities in such enzymes. In this context, we were curious to explore the case of enterocin 96 -a bacteriocin purified originally from E. faecalis WHE 96. Enterocin 96 is characterized as a linear, nonpediocin-like class II bacteriocin (Izquierdo et al. 2009 ). The calculated mass of the purified enterocin 96 was 314.94 Da smaller than the experimental mass obtained, thereby suggesting the presence of a post-translational modification (most likely glycosylation) in the said peptide. The activity spectrum of enterocin 96 is fairly broad. It exhibits high antibacterial activity against food-borne Grampositive pathogens, namely Listeria monocytogenes and Staphylococcus aureus. Therefore, enterocin 96 is a potential candidate for application in food preservation (Izquierdo et al. 2009 ). Interestingly, ORF0422 of Enterococcus faecalis TX0104 -a vancomycin-resistant clinical isolate of human microflora is a sequence homolog of enterocin 96 and encodes for a prebacteriocin of the same. Similarly, the genetic context of ORF0422 and sequence analysis of neighboring ORF0417 suggested ORF0417 to encode for a glycosyltransferase (termed EntS, here) of GT-2 family. EntS has~30% sequence homology to SunS and ThuS (Oman et al. 2011) . In this study, we identify and validate EntS as a relaxed specificity O-and S-glycosyltransferase that is capable of transfer as well as extension of the glycan on to Ser, Thr and Cys residues of the acceptor peptide in an iterative sequential dissociative manner. We further provide a method to generate glycovariants of enterocin 96 peptide (EC) using EntS as a tool, whereby both size and identity of glycan are found to affect the bioactivity of the peptide. Finally, we provide biochemical evidence that only glucosylated forms of enterocin 96 peptide are bioactive and display antimicrobial activity against L. monocytogenes EGD-e.
Results and discussion
ORF0422 and ORF0417 of Enterococcus faecalis TX0104 are co-transcribed in a putative enterocin 96 biosynthesis cluster of genes
The glyco-bacteriocins as discussed in Table I and their corresponding glycosyltransferase-encoding genes are present as part of a bacteriocin biosynthesis gene clusters in Bacillus subtilis 168, Lactobacillus plantarum KW30, Bacillus thuringiensis BGSC 4AW1 and Enterococcus faecalis F4-9 genomes, respectively. In silico sequence analysis of ORF0422 suggested the similar genetic context of enterocin 96 biosynthesis gene cluster in Enterococcus faecalis Strain TX0104. To verify the presence of predicted ORF0422 and ORF0417, in cellular milieu, the bacteria was grown in Brain Heart Infusion (BHI, Himedia USA) media and total RNA was extracted by chloroform phase separation. The isolated RNA was then converted into cDNA and used for RT-PCR experiments, as described in Materials and methods. The presence of transcripts corresponding to ORF0422 and ORF0417 as well as their co-transcription with adjacent genes of putative enterocin 96 biosynthesis gene cluster was verified in total cellular RNA pool of the bacteria, as illustrated in Figure 1 . Various gene-specific primers and junction primers used in RT-PCR are listed in Supplementary data, Table SIII sections i and ii, respectively.
EntS can transfer and extend the glycan at Ser 33 residue in enterocin 96
Post confirming the presence of RNA transcripts and co-transcription of ORF0417 with ORF0422 in E. faecalis TX0104, ORF0417 was cloned, expressed and the protein EntS was purified to >95% homogeneity from E. coli. Purified EntS has the monomeric mass of 54,156 Da and a CD estimated 77.3% α-helical and 1.7% β-strand content (Figure 2) . The sedimentation velocity profile of EntS acquired using analytical ultracentrifugation suggests that it behaves as a dimer in solution (Supplementary data, Figure S1 ). Using custom synthesized leaderless enterocin 96 peptide (termed EC, having a calculated average mass of 5179.00 Da) as acceptor substrate (Supplementary data, Table SI ) and UDP-Glc as donor substrate glycosyltransferase activity of purified EntS was assayed, as described in Materials and methods. In view of sequence homology of EntS to known hexosyltransferases: SunS and ThuS (Table I) , UDP-Glc was used as the donor substrate. LC-ESI-MS readouts of assay reactions revealed the generation of both, single-and double-glucosylated EC (5341.36 Da and 5503.52 Da, respectively) in 30 min. Parameters for in vitro GT assays were optimized as explained in Supplementary data, Figure S2 . Under these optimized assay conditions, complete Figure 3A) . Analysis of chymotrypsin-digested, double-glucosylated EC, using MALDI-TOF MS and tandem MS, confirmed di-glucosylation of single serine residue Ser33 (glycosite) on EC acceptor peptide ( Figure 3C and E). While optimizing the assay conditions, we additionally observed that cytoplasmic EntS was active in the presence of nonionic detergents, namely 0.1% TritonX114, 0.1% NP-40 and 1% of Tween 20, as often appreciated in the case of membrane-associated GTs (Supplementary data, Figure S2E ).
EntS can catalyze both O-and S-glycosidic linkages in acceptor peptide
The ability of EntS to transfer a hexose and then polymerize it into a di-hexose at a particular residue-Ser33 in EC was further investigated, using the custom synthesized chemovariants of EC peptide as acceptors. Ser at position 33 was replaced with residues possessing different side chains namely, Asn, Thr, Cys and Tyr (Supplementary data, Table SI ). MS and tandem MS analysis confirmed chemoselective di-glycosylation of the hydroxyl group of Thr (Thr33 in ECS33T) (Supplementary data, Figure S3C and S3D) and the thiol group of Cys (Cys33 in ECS33C) ( Figure 3B , D and F) but not amide group of Asn (Supplementary data, Figure S3E ). A regioselectivity for Ser, Thr over Tyr may exist as ECS33Y remained unglycosylated in our experiments (Supplementary data, Figure S3F ). Thus, from these results, EntS is identified as a peptide GT capable of both O-and S-di-glycosylation, in vitro.
EntS has relaxed donor substrate specificity
Next, the donor specificity of EntS was tested using 1 -5 mM of different donor sugars as described in Materials and methods and discussed in Supplementary data, Figure S4 . In our experiments, EntS could utilize both UDP-and GDP-linked hexoses namely, glucose and galactose effectively, but not GDP-mannose or GDP-fucose or the substituted hexoses (GlcNAc, GalNAc and glucuronic acid). Relaxed specificity for the activating nucleotide is not common for peptide GTs. However, all three, SunS, ThuS and EntS can turn over GDP-linked hexoses albeit with varying efficiencies. Previously, Nglycosyltransferase (NGT) from Actinobacillus pleuropneumoniae is known to utilize both UDP-and GDP-linked sugars (Naegeli et al. 2014a) . Interestingly, NGT (soluble GT-41 enzyme from Haemophilus influenza) was originally proposed to have dual ability to transfer a monosaccharide (Glc/Gal) on an acceptor residue (Ser/ Thr/Cys for EntS, Asn for NGT) and then extend the glycan chain into a disaccharide. However, later in a homologous system in A. pleuropneumoniae, it was found that NGT can transfer only a monosaccharide on to the acceptor protein and it does require another enzyme to extend the glycan chain Choi et al. 2010) . Although, engineered macrolide GT variants are known to glycosylate a range of O-, S-and N-nucleophiles, EntS is unique enzyme as it alone can catalyze both transfer and extension of a glycan on the acceptor peptide to form O-or S-glycosidic linkages, in one pot in vitro.
Acceptor substrate specificity of EntS and identification of minimal sequon
The custom synthesized core peptides of known bacteriocins and their variants namely GccF core peptide, SunA core peptide, SunA1-27 (Wang and van der Donk 2011), SunA1-27,C22S and SunAG21D,C22S,G23S,G24D were tested as acceptors, to decipher the substrate specificity of EntS. In acceptor sequence SunA1-27, C22S, the native glycosylating residue Cys22 was replaced with Ser22 and in SunAG21D,C22S,G23S,G24D, "GCGG" stretch of SunA1-27 was replaced with DSSD. From the results of GT assays summarized in Supplementary data, Figure S5I and Table SI , we identify that EntS does not utilize any of these peptides as its acceptor substrate. Knowing that GccF core peptide is an anticipated substrate for GccA (Table I) and SunA core peptide is a known substrate for SunS and ThuS, we conclude that substrate preference of EntS is different from that of SunS, ThuS and may be GccA, too. Further, the EntS sequon was defined by using the custom synthesized variants of acceptor substrate EC at positions flanking glycosite (Ser33). The glycosite Ser33 in the core EC peptide is flanked by an acidic residue, Asp32 at N-terminus and a polar residue Ser34, and an acidic residue Asp35 at C-terminus. Using single-residue variants of the EC peptide, namely ECΔD32, ECD32R and ECD32E, the acidic residue at the penultimate (i.e., −1) position of the glycosite was identified crucial for Ser33 glycosylation. Similarly, Ser34 at +1 position of the glycosite, though replaceable with Thr, Ala (ECS34T, ECS34A), was found indispensable (ECΔS34) for glycosylation by EntS. However, Asp35 at +2 position of the glycosite (ECΔD35) was not required for glycosylation. Interestingly, using ECS34R as a substrate where flanking Ser34 is replaced with a basic residue Arg, poor monoglucosylation (wherein <1% substrate got converted into the product) could still be detected. Nonetheless, results with ECΔS34 and ECS34R together suggest that charged residues are unfavorable at position 34 (Supplementary data, Table SI, Figure S5II ). Next, different N-and Cterminal truncations of the acceptor peptide EC were tested, where EntS modified all but EC21-33 in overnight assays (Supplementary data, Figure S6 ). From the results given in Supplementary data, Table SI and Figures S3A, S3B , S5 and S6, we identify residue length 17-36 as optimal for di-glycosylation. Accordingly, the sequence IHSLLNRLGG (D/E≠G/R) (S/T/C≠Y/N) (S/T/R/A≠G/D) is the "minimal sequon" sufficient for glycosylation by EntS.
EntS employs single active site for di-glycosylation
The protein sequence of EntS contains single conserved DXD motif at N-terminus. In inverting enzymes, the interaction of last Asp of DXD with divalent cation and that of variable residue X, (usually a polar or an aliphatic residue of moderate size) with ribose is well known (Breton et al. 2006) . As anticipated, the presence of 1mM ethylenediaminetetraacetic acid (EDTA) in GT assay completely inhibited the enzyme activity confirming the metal dependence of EntS, possibly through DXD motif ( Figure 4A ). Multiple-sequencealigned, conserved residues along with DXD motif in N-terminus of EntS were then mutated to create 14 different site-directed mutants of EntS to screen for change in GT activity (Supplementary data, Figure S7A and Figure 4B ). Ala substitution at Arg136, Trp147, Asp152, Asp154 and double substitution at Asp130-Asp131, Asp131-Phe132 (to Asp) compromised enzyme activity, completely.
These residues further colocate in a meaningful context in the putative sugar binding pocket surrounding DXD motif (Supplementary data, Figure S7B and Figure 4B inset). Mutations in Asp152 or Ala153 or Asp154 (representing DXD motif), all led to the abolition of EntS activity meaning DAD motif is essential for both the mono-and di-glycosyltransferase activities of EntS. It also suggests that EntS employs same active site for sequential diglycosylation, hence iterative in action (Supplementary data, Figure S8 ). Although iterative glycosylation is well established in GTs glycosylating macrolides (Zhang et al. 2006) , EntS provides the first example of O-/S-glycosyltransferase that acts iteratively on to a protein substrate. EntS utilizes sequential dissociative mechanism for iterative di-glycosylation Mechanism of sugar transfer on to the protein could be en-bloc or sequential. In en-bloc transfer, the glycan is first assembled on a carrier molecule and then transferred as single unit, in single reaction on a protein/peptide residue. Whereas, in sequential mechanism, the glycan is directly and sequentially assembled on to the protein by one or more GTs. Further in sequential mechanism if only one GT is involved it could be processive (May et al. 2012) or nonprocessive. Nonprocessive glycosylation is also termed as sequential dissociative mechanism (Troutman and Imperiali 2009) . To understand the mechanism of transfer of two hexoses on to the EC peptide by EntS, the product formation was monitored by varying the reaction time while keeping the other reaction conditions identical ( Figure 5D ). Similarly, enzyme: substrate ratio was varied from 1:100 to 1:10 in a 20 min' long GT assay using 2.5 μM of substrate peptide ( Figure 5A ). Analysis of ratio of modified/unmodified peptide ( Figure 5B and C) indicated that during early reaction phase (lower enzyme concentration, early reaction time points), mono-glycosylation is the primary reaction whereas in the later phase, di-glycosylation takes over. Presence of mono-glycosylated peptide (reaction intermediate) at all early time points of reaction indicates free dissociation and association of intermediates with the enzyme, thereby confirms a dissociative sequential mechanism of glycan transfer by EntS ( Figure 5E ). Similar mechanism is reported for PglH, a processive sugar polymerase of Campylobacter jejuni, previously (Troutman and Imperiali 2009 ). In bacteria, though both en-bloc and sequential mechanisms are known (Larkin and Imperiali 2011; Schwarz and Aebi 2011; Iwashkiw et al. 2013; Valguarnera et al. 2016) , sequential N-glycosylation (Naegeli et al. 2014a (Naegeli et al. , 2014b and en-bloc O-glycosylation (Iwashkiw et al. 2013 ) are unique to prokaryotes. In this study, we provide the first example of sequential S-glycosylation by a bacterial GT that strengthens the idea that bacterial protein GTs are much more versatile than their eukaryotic counterparts.
EntS can catalyze β-linkage at terminal position in diglycan attached to the acceptor peptide ThuS and SunS-the EntS homologs, are known to catalyze β linkage between acceptor peptide and the glycan. Therefore, diglucosylated EC was subjected to enzymatic deglycosylation using β-glucosidase to determine the stereochemistry of the attached disaccharide glycan. The approximately two-third population of diglucosylated EC got converted into mono-glucosylated EC, as observed in LC-ESI-MS spectra of the enzyme digest ( Figure 6 ). Several enzymatic deglycosylation assays (Supplementary data, Table SII) were set up to decipher the glycan further. However, either degradation of the peptide during deglycosylation assays or may be nonoptimum enzyme digestion conditions have prevented us from precise identification of proximal linkage, in our experiments. In this context, an interesting example of GT catalyzing variable alternate β(1→5) and β(1→6) linkages using the single active site (May et al. 2012 ) is known in galactofuranosyltransferase (GlfT2). GlfT2 is an essential protein involved in galactan biosynthesis in the mycobacterial cell wall. For technical issues detailed above, the stereochemistry of the proximal linkage is still a curiosity-under investigation in our laboratory. . EntS is a metal-dependent iterative glycosyltransferase of the GT-2 family. (A) GT assays were set up in the presence or absence of EDTA, a metal chelator to decipher the requirement of the metal ion for enzyme activity. Complete di-glucosylation of EC observed in the presence of 1 mM MgCl 2 , while partial mono-glucosylation of EC was observed in the absence of externally added MgCl 2 and EDTA. The partial enzyme activity may be due to cellular metal ion carryover in the enzyme preparation. Upon addition of 1 mM EDTA (with no external MgCl 2 supplement) in the GT assay, glycosylation did not happen. It confirmed the metal ion dependence of EntS. Theoretical average masses of unglycosylated and glycosylated EC peptide are cited in SIV (S. No: 6). (B) A comparison of enzyme activities of the site-directed mutants of EntS, where x-axis depicts mutants and y-axis provides the GT activity as the ratio of the abundance of ions of glycosylated EC/unglycosylated EC (G/U). The inset highlights colocalization of critical residues (in red) around DXD motif along with its putative active site. This figure is available in black and white in print and in color at Glycobiology online.
Glycovariants of acceptor peptide EC exhibit differential antimicrobial activity against Listeria
Native enterocin 96 is known to have strong antimicrobial activity against L. monocytogenes EGD-e, a common food pathogen (Izquierdo et al. 2009 ). Therefore, the significance of glycosylation in bioactivity of the leaderless linear enterocin 96 peptide (EC) was studied using agar diffusion assays with L. monocytogenes EGD-e as indicator strain. Accordingly, this study presents biochemical evidence that enterocin 96 encoded by ORF0422 in Enterococcus faecalis TX0104 is a di-glycosylated bacteriocin and active in glucosylated form only. The unglycosylated linear EC peptide was identified as a random coil in CD spectroscopic analysis and found inactive against L. monocytogenes EGD-e in agar diffusion assays. However, upon glycosylation, the EC peptide adopted helical configuration and achieved bioactivity against L. monocytogenes EGD-e ( Figure 7D ). From this, we concluded that unlike SunS and ThuS that require an N-terminal helix preceding glycosite Wang et al. 2013) , EntS could glycosylate a random coil, albeit with sequon preference mentioned above. Similarly, CD analysis provides direct evidence that di-glycosylation is important for inducing helical configuration in the linear unglycosylated EC peptide. Further to decipher whether helical configuration alone is sufficient to impart bioactivity to the unmodified linear EC, TFE treatment was employed. The linear unmodified EC peptide was induced to form a helix in the presence of varying concentrations of TFE ranging from 10% to 50% v/v. However, TFE treated EC peptide was not active against L. monocytogenes EGD-e implying that being helical is not sufficient for bioactivity of EC. This observation is in contrast to the findings made in the case of sublancin 168 wherein double helix bundle is critical for bioactivity of the said glyco-bacteriocin. Similarly, the disulfide linkages are considered essential for bacteriostatic effect in all the known glyco-bacteriocins that are discussed in Table I . As EC peptide sequence harbors five cysteines, we next explored the requirement of disulfide linkages for its bioactivity. The reduction and alkylation were done before and after performing the glycosylation on EC peptide. These modified peptides were then tested for their bioactivity as stated in the Materials and methods. Here, we identify that alkylated and reduced form of glycosylated EC is as bioactive as nonreduced, nonalkylated but glycosylated EC. From this, we conclude that disulfide linkages are not essential for bioactivity of EC peptide against L. monocytogenes EGDe ( Figure 7B and Supplementary data, Figure S9) . Further, the nature of glycosylating residue also did not affect bioactivity as both fulllength EC as well as its chemovariant ECS33C (S33 substituted with Cys33) were active against L. monocytogenes EGD-e in agar diffusion assay upon glycosylation. However, all truncated versions of fulllength EC were found inactive indicating that shorter lengths could be insufficient to impart structure necessary to obtain bioactivity.
Glycosylation though seemed important for bringing in the order in random coil structure of the unglycosylated linear peptide; TFE induced helical EC was not bioactive. Therefore, we next explored the additional significance of di-glycosylation. Previously, the nature of glycan is not known to affect bioactivity in sublancin and thuradacin except in the case of plantaricin, wherein GlcNAc is essential for bacteriostatic effect. To investigate the case of enterocin 96, we first standardized a controlled GT assay by modulating the enzyme: acceptor substrate ratio so as to obtain both mono-and di-glycosylated products. Further, an RP-HPLC method was developed (described in Materials and methods) to separate di-glycosylated, mono-glycosylated and un-glycosylated EC peptide ( Figure 7C ). Subsequently, using EntS as an enzyme, glycovariants of EC peptide were prepared as illustrated in Figure 7A and all were tested to identify a correlation between nature of glycan and their bioactivity, respectively. Our results as depicted in Figure 7B suggest that equal concentration of di-glucosylated EC is more bacteriostatic than mono-glucosylated EC. EC having galactose at the terminal position remains inactive against the indicator strain in the bioactivity assay. While the presence of glucose at terminal position in EC is critical for its antimicrobial activity. Thereby, both nature and number of sugars attached to EC peptide affect its bioactivity against Listeria species.
Conclusion
In this study, we characterize a new glycosyltransferase of bacterial origin that has unique abilities to transfer as well as extend a monosaccharide iteratively in a sequential dissociative manner onto its acceptor substrate and generate O-as well S-linked glycovariants of its acceptor. The donor specificity, acceptor sequence specificity and minimal sequon required for glycosylation by EntS is also deciphered. Additionally, we provide methods to generate and separate glycovariants of acceptor peptide that are differentially bioactive against L. monocytogenes EGD-e. The differences observed in the bioactivity of the glycovariants of enterocin 96 peptide, confirm that the size and identity of glycan influence the activity of the said antimicrobial peptide. As seen in the case of ThuS and SunS and considering sequence preferences of GT's, possibilities of di-glycosylation and glycodiversification of any polypeptide harboring accessible "EntS minimal sequon" is anticipated, though not tested. Given the ability of EntS to engineer multiple linkages namely, Glc/Gal(→O) Ser/Thr, Glc/Gal(→S)Cys and Glc/Gal(β)Glc/Gal(→O/S)Ser/Thr/Cys, EntS does make an enzyme worth pursuing. Owing to the potential applications of antimicrobial peptides and their glycovariants in therapeutics, cosmetics or agri-products (Hassan et al. 2012; Cotter et al. 2013; Subramanian and Smith 2015) , we believe EntS can be a useful enzyme, if developed further. The observed correlation between the size of the glycan and antimicrobial activity of enterocin 96 points to the possibilities of modulating antimicrobial activities of similar peptides by changing the size of the glycan attached.
Materials and methods

Reagents
The custom synthesized, codon optimized gene was obtained from GenScript, USA. Custom synthesized peptides were obtained from Lifetein, USA and G L Biochem, China. All oligonucleotides were purchased from Sigma. Media components for bacterial culture were purchased from Himedia. DNA polymerase, restriction endonuclease and T4 DNA ligase were purchased from New England Biolabs (NEB). Chemicals used in RT-PCR were purchased from Fisher Scientific and Ambion. Chymotrypsin and other chemical reagents used in mass spectrometry were purchased from Sigma Aldrich.
Notation
Throughout the manuscript, the CFG (Consortium of Functional Glycomics) nomenclature is adopted to represent glycans in figures and schemes. The mass spectrometry readouts (spectra) for enzyme assays (EntS) are plotted in red whereas control reactions (without enzyme) are plotted in black, unless mentioned otherwise.
RNA extraction
Enterococcus faecalis strain TX0104 was grown in Brain Heart Infusion (BHI, Himedia) broth in the presence of 0.05% Tween 80 and 10 μg/mL of vancomycin at 37°C until log phase. The cell pellet was resuspended in TRIzol reagent (Ambion) and lysed in Fastprep at maximum speed using glass beads (Sigma Aldrich, USA). A good quality RNA was extracted using chloroform phase separation. RNA was precipitated from aqueous layer using isopropanol. RNA preparation was treated with RNase-free DNase I (Ambion) for 30 min at 37°C. It was further purified using RNeasy MinElute Cleanup kit (Qiagen), followed by DNase I treatment for 45 min at 37°C to ensure proper removal of genomic DNA. DNase I was inactivated at 75°C for 5 min in the presence of 5 mM EDTA. The concentration and quality of purified RNA was checked at Tecan (Infinite 200Pro) and agarose gel electrophoresis. Only good quality RNA was used for first strand cDNA synthesis and RT PCR.
cDNA synthesis and reverse transcription PCR (RT-PCR)
cDNA synthesis was done using random hexamer primers and RevertAid Reverse Transcriptase (Fermentas) at 42°C for 60 min. Reverse transcriptase (RT) was inactivated at 70°C for 5 min. The synthesized cDNA was used for downstream RT-PCR amplification. Various RT-PCR reactions were set with c-DNA using the gene specific primers and junction primers (listed in Supplementary data, Table SIII sections i and ii) to confirm the presence of transcripts in cellular RNA pool and co-transcription of adjacent genes of putative enterocin biosynthesis gene cluster. The purified RNA treated with DNase I for 45 min at 37°C, followed by heat inactivation of DNase I at 75°C for 5 min in the presence of 5 mM EDTA, served as negative control for RT-PCR reactions.
In vitro glycosyltransferase (GT) assay
The in vitro glycosyltransferase assay of EntS was set up using 5 μM synthetic acceptor peptide, 0.1 mM UDP-Glc and 0.2 μM of purified EntS, in a buffer containing 20 mM HEPES, pH 7.5, 50 mM NaCl, 2 mM DTT/1 mM TCEP and 1 mM MgCl 2 at 25°C for 12 h, unless mentioned otherwise. Each assay reaction was accompanied by (a) buffer alone control, (b) reaction control without enzyme (EntS) and (c) enzyme alone in assay buffer (used with every new lot of purified protein) to rule out any artifacts. A 10× scale-up of optimized assay concentrations was employed (keeping buffer conditions same as above) to define the substrate specificities, minimal sequon and activity of site directed mutants. A positive control reaction was also set up wherever necessary, using custom synthesized substrate peptide SunA1-27 (Supplementary data, Table SI) as acceptor (50 μM), UDP-Glc (5 mM) as donor and 2 μM of SunS as enzyme. pET28bSunS construct was transformed in E. coli Lemo21(DE3) and protein SunS was purified as described previously (Oman et al. 2011) . All assay reactions were quenched with 5% TFA to pH 2.0, cleaned-up using ZipTip C 18 (Catalog No: ZTC18S096, Millipore), vacuum dried and reconstituted either in 1:1 (v/v) ratio with CHCA matrix solution for MALDI-TOF MS analysis or in 0.1% formic acid for LC-ESI-MS analysis.
Annotation of glycosite using chymotrypsin digestion
Glycosylated acceptor peptides (50 μM) were cleaned-up using ZipTipC 18 and digested using Chymotrypsin (Catalog No: C 6423, Sigma Aldrich). The digestions were carried out using a 1:25 ([E]:
[S]) ratio in 100 mM Tris-Cl, pH 7.5, 10 mM CaCl 2 and 5 mM TCEP at 30°C for 5 h. The digests were then quenched with 5% TFA to pH 2.0, cleaned-up using ZipTipC 18 , vacuum dried and subjected to MALDI-TOF MS and tandem MSMS analysis.
Site-directed mutagenesis
Various point mutations were introduced in EntS using the QuickChange Lightning Site-Directed Mutagenesis kit (Catalog No: 210,519, Agilent Technologies), as per recommended protocol by manufacturer. EntSpET28a plasmid was used as template. Primers designed and used for site-directed mutagenesis are listed in Supplementary data, Table SIII, section iii. Mutations were confirmed by plasmid DNA sequencing. Mutants were transformed into E. coli BL21(DE3) cells for expression and purification as described in the section Over-expression and purification of EntS. Purified EntS variants were assayed against EC peptide as described in the section In vitro GT assay.
Deglycosylation of di-glucosylated EC
The di-glucosylated EC was deglycosylated using suitable exoglycosidase (β-glucosidase). The EC was first di-glucosylated under aforesaid optimized conditions under section In vitro GT assay. Di-glucosylated EC peptide (5 μM) was then incubated with 2 μg/μL of β-glucosidase (Catalog No: 195, 197 , MP Biomedicals) in a reaction buffer containing 100 mM sodium acetate buffer, pH 5.0 and 1 X purified BSA for 18 h. The control reaction was carried out by incubating all reaction components in the absence of β-glucosidase. The reactions were quenched with 5% TFA to pH 2 and subjected to LC-ESI-MS analysis without desalting.
Controlled GT assay and HPLC method to prepare glycovariants of EC The GT assay conditions were optimized to get a mixture of unglycosylated, mono-glycosylated and di-glycoyslated EC peptide. EC peptide (100 μM) was incubated with 0.25 μM EntS ([E]: [S] = 1:400) and 100 μM UDP-Glc/UDP-Gal for 1 h at 25°C. The reactions were analyzed on analytical HPLC system (Shimadzu) using a reverse phase column of Phenomenex (Jupitor 5 μm C18 column, 250 × 4.6 mm 2 , 300 Å). RP-HPLC method was further optimized to separate the mixture of un-glycosylated and mono-glycosylated and di-glycosylated EC peptide. 20 μL of the reaction mixture was injected on the column previously equilibrated with 5% solvent B (solvent A: 0.1% TFA in water, solvent B: 0.1% TFA in ACN). The sample was fractionated by employing a gradient of solvent B (5-100%) over 26 min with a flow rate of 1 mL/min and observed at a wavelength of 220 nm. The mass of separated species was checked by MALDI-TOF-MS, which confirmed that di-glycosylated EC elutes first, followed by mono-glycosylated and then unglycosylated EC peptide. The purified HPLC fractions containing single species were lyophilized and stored at −80°C. The HPLC purified mono-glucosylated EC peptide was glycodiversified using UDP-Gal and EntS under optimized GT assay conditions. Similarly, monogalactosylated EC peptide was glyco-diversified using UDP-Glc and EntS. The mass of glycovariants was confirmed by LC-ESI-MS.
Acquiring CD spectra of EntS and the EC peptide
The CD experiments were performed to check the secondary structure of EntS protein using JASCO J-815 CD spectrometer. 2 μM of purified EntS in 20 mM HEPES, pH 7.5 and 0.5 mM DTT was used to acquire CD spectrum. Similarly, the spectra was acquired for 10 μM un-glycosylated EC, both in water and 20% trifluoro ethanol (TFE) and di-glucosylated EC in water. The spectra was acquired at 20°C in far UV range of 200-250 nm, keeping the data pitch 0.5 nm, bandwidth 1.0 nm and scanning speed 50 nm/min. Measured values of ellipticity (θ) were converted to mean residue ellipticity [θ] and molar absorption (Δε) using the formula:
Where, MRW is mean residue weight (molecular weight of protein/number of amino acid residues), P is path length in mm, and concentration of protein sample in mg/mL. CD data was then interpolated using Origin software (OriginPro2015, b9.2.214). K2D2 online server (http://k2d2.ogic.ca/, last accessed on 18 May 2017) was used for estimation of secondary structure elements in the protein.
Bioactivity assay of EC peptide
Di-glycosylated, mono-glycosylated and un-glycosylated forms of EC peptide were prepared using controlled GT assays and purified using RP-HPLC. The peptide species were prepared for bioactivity assay by re-suspending the lyophilized species in 50 mM Tris-Cl, pH 7.5. Similarly, glycovariants were also prepared and used for bioactivity assay. The culture of L. monocytogenes EGD-e was grown in BHI media at 37°C for 7-8 h. Agar plates were prepared by mixing 25 μL of saturated culture (A 600 ≈ 1.5) and 100 mL of molten BHI agar (cooled to 40-45°C) and pouring the mixture into sterile petri plates. The seeded agar plates were allowed to solidify for 30-45 min and agar wells were prepared using a sterile cork borer. 50 μM of all peptide species were poured to the wells and plates were incubated at 37°C for 12 h. The antimicrobial activity was determined by the presence and absence of zone of growth inhibition.
Role of disulfide bonds in bioactivity
50 μM of un-glycosylated EC and di-glycosylated EC was reduced using 10 mM DTT for 1 h at 25°C followed by alkylation using 50 mM iodoacetamide for 3 h at 25°C in the dark. Similarly, reduced, alkylated EC was di-glucosylated under optimized assay conditions. LC-ESI-MS confirmed the reduction and alkylation of un-glycosylated/di-glycosylated EC and then all the species were screened for bioactivity against L. monocytogenes EGD-e.
Supplementary data
Supplementary data is available at Glycobiology online.
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